Side-by-side comparison of AI visibility scores, market position, and capabilities
Tucuvi's LOLA is the first EU Class IIb certified AI medical voice agent; in 60+ health systems with $20M Series A, running post-discharge follow-ups and chronic care check-ins (Jan 2026).
Tucuvi is a Spanish clinical AI company that has developed LOLA, a conversational voice AI agent for healthcare. LOLA conducts automated clinical conversations with patients — including post-discharge follow-ups, chronic disease monitoring check-ins, pre-appointment screenings, and medication adherence calls — with the tone, clinical accuracy, and empathy expected of a skilled nurse or care coordinator. Tucuvi was founded by a team combining clinical expertise and AI engineering to address the growing gap between care demand and available clinical staff in European health systems.\n\nThe LOLA platform integrates with hospital information systems and electronic health records, enabling health systems to deploy automated voice interactions at scale across their patient populations. The system is multilingual and capable of conducting clinically meaningful conversations that capture structured data, flag deteriorating patients, and escalate to human clinicians when needed. Unlike general-purpose voice assistants, LOLA is specifically trained on clinical language, patient interaction patterns, and healthcare workflows.\n\nTucuvi achieved a landmark regulatory milestone by becoming the first EU Class IIb certified AI medical device in the voice AI category, a certification level that covers devices posing moderate to high risk — the same classification as many implantable devices. This certification is a significant commercial differentiator in Europe's tightly regulated healthcare market. The company raised a $20M Series A, serves 60+ health systems, and has conducted 300,000+ clinical voice calls. Its 2025–2026 momentum reflects growing European health system interest in AI that can extend care capacity without adding nursing headcount.
Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.
Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.